Expression of nerve growth factor in the airways and its possible role in asthma

https://doi.org/10.1016/S0079-6123(03)46021-4Get rights and content

Abstract

Nerve growth factor (NGF), in addition to its essential role in neuronal growth and survival, may also act as an inflammatory mediator. As several animal studies have shown, NGF appears to play a part in the development of airway hyperresponsiveness and in the increased sympathetic and sensory innervation of the lung. It also has a profound effect on airway inflammation and asthma-related symptoms. Sources of NGF in the airways are numerous: inflammatory cells infiltrated into the bronchial mucosa, and structural cells including lung fibroblasts, airway epithelial and smooth muscle cells. These cells, by releasing more NGF in inflammatory conditions, may contribute to the increased NGF levels observed in bronchoalveolar lavage fluid and serum from patients with asthma. Taken together, these results suggest that NGF is an important mediator in both inflammation and asthma.

Introduction

Nerve growth factor (NGF) was discovered by Rita Levi-Montalcini and co-workers more than 50 years ago (reviewed by Levi-Montalcini et al., 1995, Levi-Montalcini et al., 1996). It belongs to the neurotrophin family of proteins, which also includes brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) and NT-4/5 (Barde, 1990). NGF is essential for the survival and development of peripheral and brain neurons (Levi-Montalcini, 1966; Levi-Montalcini and Aloe, 1985; Levi-Montalcini, 1987; Thoenen et al., 1987). It may also be involved in inflammation. This review examines the current literature about NGF expression and regulation in the airways and summarizes the findings that suggest that it may have a role in asthma.

Section snippets

Sources of NGF in the airways

Mouse salivary glands, mouse sarcoma and snake venom were the first sources of NGF to be discovered (Aloe and Levi-Montalcini, 1980; reviewed by Levi-Montalcini, 1987), but studies since then have found a broad range of cells able to synthesize and secrete NGF. Its sources in the airways include inflammatory cell infiltrates of the bronchial mucosa as well as structural cells (Fig. 1).

Inflammatory cells

NGF production was first discovered in cells from the peripheral and central nervous system, but studies in the 1990s also reported that it is secreted by cells of the immune system (Aloe et al., 1994; Levi-Montalcini et al., 1995, Levi-Montalcini et al., 1996). Indeed, T and B lymphocytes (Ehrhard et al., 1993; Santambrogio et al., 1994; Torcia et al., 1996; Lambiase et al., 1997), mast cells (Leon et al., 1994; Nilsson et al., 1997), eosinophils (Solomon et al., 1998; Kobayashi et al., 2002)

In vivo studies

The in vitro secretion of NGF in cultured cells accords fully with reports of NGF-positive immunolabeling in bronchial biopsy samples from patients with or without asthma (Kassel et al., 2001; Olgart-Höglund et al., 2002). NGF immunolabeling is intense in bronchial epithelium and the bronchial smooth muscle layer, but less intense in airway fibroblasts (Fig. 3a,b). In bronchial biopsy samples from asthmatic patients, the inflammatory cell infiltrate also shows NGF immunolabeling (Kassel et al.,

Regulation of NGF expression in the airways

The mechanisms regulating the production and release of NGF in the airways in vivo require further study, but for the time being, in vitro experiments provide some information. Examination of the regulation of NGF expression during cell proliferation and quiescence shows that NGF secretion in lung fibroblasts (Olgart and Frossard, 2001) and in airway smooth muscle cells (Freund et al., unpublished data) depends on cell density. That is, NGF secretion is high when the cell culture begins and

Upregulation of NGF in inflammatory conditions

NGF expression also appears to be modulated by inflammatory mediators in the airways. Inflamed airways contain increased levels of NGF (Sanico et al., 2000; Olgart-Höglund et al., 2002), perhaps due in part to an increase in the number of inflammatory cells that infiltrate the bronchial mucosa and release NGF (reviewed by Olgart and Frossard, 2002). Autocrine or paracrine NGF may activate many or most of these inflammatory cells, which then release proinflammatory cytokines, which may in turn

Downregulation of NGF by anti-inflammatory drugs

Because corticosteroids are known to have anti-inflammatory effects and to be clinically effective in suppressing inflammation in the lungs and airways, researchers have examined the effect of two of them, budesonide and dexamethasone, on NGF secretion. Lindholm et al. (1990) reported that glucocorticoids downregulate cytokine-stimulated NGF expression by repressing NGF gene transcription in cultured sciatic rat fibroblasts. Our team found that glucocorticoids downregulate cytokine-induced NGF

Action on neuronal cells

Transgenic mice that overexpress NGF in the lungs show marked airway hyperinnervation of sensory and sympathetic fibers; under electric field stimulation, they release increased quantities of substance P (SP) (Hoyle et al., 1998). This result is consistent with findings that NGF can stimulate neuron development, growth and survival, particularly of the sensory and sympathetic innervation (Levi-Montalcini, 1987). Indeed, these neurons express NGF receptors (Verge et al., 1989; Lee et al., 1992;

Action on inflammatory cells

NGF activates cells through two types of cell surface receptors: the receptor tyrosine kinase A (TrkA), which has a high affinity for NGF, and the p75 neurotrophin receptor (p75NTR), with low affinity for NGF (Barbacid, 1995; Greene and Kaplan, 1995; Segal and Greenberg, 1996; Kaplan and Miller, 1997). Most inflammatory cells can produce NGF and also express both of these NGF receptors. For example, TrkA receptor has been found on human mast cells (Tam et al., 1997; Nilsson et al., 1997), in

NGF action on structural cells

Although the action of NGF on airway structural cells remains to be further elucidated, recent studies certainly suggest that there are effects (Table 1). NGF stimulates the contraction and migration of lung fibroblasts (Micera et al., 2001, Kohyama et al., 2002) and vascular smooth muscle cells (Kraemer et al., 1998); it also induces the proliferation of airway smooth muscle cells (Freund et al., 2003). These results suggest that NGF plays a role in the airway remodeling that occurs in asthma.

Possible role of NGF in asthma

Accumulating studies suggest that NGF is involved in the development of inflammation in airway diseases, asthma in particular.

Conclusion

In summary, NGF levels in the airways increase in asthma and are further upregulated after allergenic challenge. NGF also appears to contribute to inflammation and bronchial hyperresponsiveness in asthmatic airways. Because in vitro studies show that NGF is upregulated by inflammatory cytokines and decreased by anti-inflammatory glucocorticoids, and because NGF effects are demonstrated in the airway remodeling, this neurotrophin should be considered a new mediator in airway inflammation. In

References (120)

  • J. Donnerer et al.

    Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo

    Neuroscience

    (1992)
  • A.J. Fox et al.

    Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases

    Eur. J. Pharmacol.

    (2001)
  • L.A. Greene et al.

    Early events in neurotrophin signaling via Trk and p75 receptors

    Curr. Opin. Neurobiol.

    (1995)
  • M. Grewe et al.

    Neurotrophin-4 production by human epidermal keratonicytes increased expression in atopic dermatitis

    J. Invest. Dermatol.

    (2000)
  • A. Hattori et al.

    Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells

    J. Biol. Chem.

    (1993)
  • A. Hattori et al.

    Tumor necrosis factor is markedly synergistic with interleukin-1 and interferon gamma in stimulating the production of nerve growth facotr in fibroblasts

    FEBS Lett.

    (1994)
  • K. Horigome et al.

    Effects of nerve growth factor on rat peritoneal mast cells: survival promotion and immediate-early gene induction

    J. Biol. Chem.

    (1994)
  • D.R. Kaplan et al.

    Signal transduction by the neurotrophin receptors

    Curr. Opin. Cell Biol.

    (1997)
  • K. Kawamoto et al.

    Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor

    Blood

    (1995)
  • H. Kobayashi et al.

    Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli

    Blood

    (2002)
  • T. Kohyama et al.

    Nerve growth factor stimulates fibronectin-induced fibroblast migration

    J. Lab. Clin. Med.

    (2002)
  • A. Lambiase et al.

    Human CD4+ T cell clones produce and release nerve growth factor and express high affinity nerve growth factor receptors

    J. Allergy Clin. Immunol.

    (1997)
  • K.F. Lee et al.

    Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system

    Cell

    (1992)
  • R. Levi-Montalcini et al.

    Update of the NGF saga

    J. Neurol. Sci.

    (1995)
  • R. Levi-Montalcini et al.

    Nerve growth factor: from neurotrophin to neurokine

    Trends Neurosci.

    (1996)
  • D. Lindholm et al.

    Interleukin-1 increases stability and transcription of mRNA encoding nerve growth factor in cultured rat fibroblasts

    J. Biol. Chem.

    (1988)
  • I. Melamed et al.

    Activation of Vav and Ras through the nerve growth factor and B cell receptors by different kinases

    Cell Immunol.

    (1999)
  • K. Murase et al.

    Human fibroblast cells synthezise and secrete nerve growth factor in culture

    Biochem. Biophys. Res. Commun.

    (1992)
  • K. Nemoto et al.

    Gene expression of neurotrophins and their receptors in cultured rat vascular smooth muscle cells

    Biochem. Biophys. Res. Commun.

    (1998)
  • F. Pons et al.

    Nerve growth factor secretion by human lung epithelial A549 cells in pro- and anti-inflammatory conditions

    Eur. J. Pharmacol.

    (2001)
  • H. Renz

    The role of neurotrophins in bronchial asthma

    Eur. J. Pharmacol.

    (2001)
  • L. Aloe et al.

    Mast cell increase in tissues in neo-natal rats injected with the nerve growth factor

    Brain Res.

    (1977)
  • L. Aloe et al.

    Nerve growth factor and autoimmune diseases

    Autoimmunity

    (1994)
  • H. Awatsuji et al.

    Interleukin-4 and -5 as modulators of nerve growth factor synthesis/secretion in astrocytes

    J. Neurosci. Res.

    (1993)
  • P.J. Barnes et al.

    Inflammatory mediators of asthma: an update

    Pharmacol. Rev.

    (1998)
  • S. Bischoff et al.

    Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils

    (1992)
  • A. Böhm et al.

    Nerve growth factor enhances precocious differentiation an numerical increase in mast cells in culture of rat splenocytes

    Accad. Naz. Lincei

    (1986)
  • S. Bonini et al.

    Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma

    Proc. Natl. Acad. Sci. USA

    (1996)
  • M.D.P. Boyle et al.

    Nerve growth factor: a chemotactic factor for polymorphonuclear leukocytes in vivo

    J. Immunol.

    (1985)
  • A. Braun et al.

    Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma

    Eur. J. Immunol.

    (1998)
  • C. Brodie et al.

    Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2

    J. Immunol.

    (1992)
  • B. Burgi et al.

    Basophil priming by neurotrophic factors: activation through the trk receptor

    J. Immunol.

    (1996)
  • A. De Vries et al.

    Nerve growth factor induces a neurokinin-1 receptor-mediated airway hyperresponsiveness in guinea pigs

    Am. J. Respir. Crit. Care Med.

    (1999)
  • A. De Vries et al.

    The role of sensory nerve endings in nerve growth factor-induced airway hyperresponsiveness to histamine in guinea pigs

    Br. J. Pharmacol.

    (2001)
  • A. De Vries et al.

    Antibodies directed against nerve growth factor inhibit the acute bronchiconstriction due to allergen challenge in guinea-pigs

    Clin. Exp. Allergy

    (2002)
  • M.J. Donovan et al.

    Neurotrophin and neurotropin receptors in vascular smooth muscle cells. Regulation of expression in response to injury

    Am. J. Pathol.

    (1995)
  • P.B. Ehrhard et al.

    Expression of functional trk protooncogen in human monocytes

    Proc. Natl. Acad. Sci. USA

    (1993)
  • P.B. Ehrhard et al.

    Expression of functional trk tyrosine kinase receptors after T cell activation

    J. Immunol.

    (1994)
  • R.A. Franklin et al.

    Nerve growth factor induces activation of MAP-kinase and p90rsk in human B lymphocytes

    J. Immunol.

    (1995)
  • V. Freund et al.

    Upregulation of nerve growth factor expression by hyman airway smooth muscle cells in inflammatory conditions

    Eur. Respir. J.

    (2002)
  • Cited by (41)

    • Fine tuning of insulin secretion by release of nerve growth factor from mouse and human islet β-cells

      2016, Molecular and Cellular Endocrinology
      Citation Excerpt :

      NGF acts via two membrane receptors: the low affinity p75NTR, an atypical member of the TNFα superfamily (Zampieri and Chao, 2006), and the high affinity trkA, belonging to the tyrosine kinase receptor family (Muragaki et al., 1995). While trkA works through phosphorylation, mainly regulating the activation of signals promoting cell survival, proliferation and differentiation (Freund and Frossard, 2004), p75NTR does not possess catalytic activity but it recruits intracellular effectors depending on its holo- (NGF-bound) and apo- (unbound) forms (Roux and Barker, 2002). In those systems expressing both receptors, p75NTR can co-operate with trkA forming a “super affinity” receptor, thus enhancing the response to low concentrations of NGF (Huber and Chao, 1995).

    • Itch sensation through transient receptor potential channels: A systematic review and relevance to manual therapy

      2013, Journal of Manipulative and Physiological Therapeutics
      Citation Excerpt :

      Nerve growth factor is responsible for the maintenance and survival of sensory neurons. Nerve growth factor expression is increased in inflammatory diseases because it suppresses inflammation.22 Nerve growth factor leads to increased density of epidermal nerve endings which increases scratching behavior.15

    • Regulation of IGF-1 but not TGF-β1 by NGF in the smooth muscle of the inflamed urinary bladder

      2012, Regulatory Peptides
      Citation Excerpt :

      Recent studies also provide strong evidence demonstrating that NGF is expressed in inflammatory conditions [7–11]. The increased NGF levels are observed in bronchoalveolar lavage fluid and serum from patients with asthma [7] and in the urinary bladder and the urine from patients with bladder inflammation [9–11]. In a CYP-induced bladder inflammation model, rats treated with CYP acutely (single dose for 4 h) or chronically (multiple dose for 10 days) [12] show increased amount of NGF mRNA or protein in the inflamed urinary bladder.

    • Localization of nerve growth factor (NGF) receptors in the mitochondrial compartment: Characterization and putative role

      2012, Biochimica et Biophysica Acta - General Subjects
      Citation Excerpt :

      Immunoprecipitation with anti-ANT (Fig. 6d) or anti-PDE4A5 (Fig. 6e) of mitochondrial fractions from whole rat brain revealed the presence of specific bands when blotted with anti-p75 indicating an interaction between the low affinity NGFR and the ANT or PDE4A5. Activation of trkA receptor leads to cell survival [2,3] therefore we investigated whether the expression of the high affinity NGF receptors in brain mitochondrial protects these organelles from Ca2+ induced swelling. Isolated mitochondria from cortex and cerebellum were exposed to a solution of 200 μM Ca2+ and concomitantly treated with or without NGF (100 ng/ml).

    View all citing articles on Scopus
    View full text